To amend the Federal Food, Drug, and Cosmetic Act to provide for the development of accelerated approval development plans for investigational drugs and biological products.
The bill’s titles are written by its sponsor.
May 21, 2015
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on May 21, 2015, in a previous session of Congress, but was not enacted.
Representative for Washington's 5th congressional district
Read Text »
Last Updated: May 21, 2015
Length: 4 pages
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
H.R. 2547 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2017). H.R. 2547 — 114th Congress: Surrogate Endpoint Improvement and Utilization Act of 2015. Retrieved from https://www.govtrack.us/congress/bills/114/hr2547
“H.R. 2547 — 114th Congress: Surrogate Endpoint Improvement and Utilization Act of 2015.” www.GovTrack.us. 2015. July 28, 2017 <https://www.govtrack.us/congress/bills/114/hr2547>
|title=H.R. 2547 (114th)
|accessdate=July 28, 2017
|author=114th Congress (2015)
|date=May 21, 2015
|quote=Surrogate Endpoint Improvement and Utilization Act of 2015
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.